The Danish pharma is trying to stay ahead of arch rivals Eli Lilly and Sanofi in an ... available to NHS patients in the UK. Lilly is developing Tempo Smart Button, a device that attaches to ...

McBain needed a victory at the court of Pine River on Tuesday to capture the Highland Conference title outright and got it, ...

Eli Lilly is betting big on its experimental oral weight-loss drug even before reporting data from its late-stage trial by ...

David Ricks said drugs like Mounjaro and Zepbound are priced to reflect the costs involved, patent expiry, and the enormous ...

For years, Eli Lilly has been generating solid growth numbers -- but lately, they've been accelerating rapidly. The company is coming off a solid quarter where its revenue rose by 45% for the last ...

Eli Lilly expands its partnership with AdvanCell to advance targeted alpha therapies using Pb-212 technology for cancer treatment. Lilly inks a global licensing deal with OliX for OLX75016 ...

On Monday, Eli Lilly And Co (NYSE:LLY) inked two strategic collaborations to expand radiopharmaceuticals and metabolic-associated steatohepatitis (MASH), respectively. AdvanCell announced that it ...

The results were consistent with the preliminary results Eli Lilly shared in January, which disappointed investors.

Eli Lilly shares rose Thursday after the drugmaker's adjusted profit came in above estimates, offsetting weaker-than-expected revenue.

OliX Pharmaceuticals announced a global licensing agreement with Eli Lilly (LLY). This collaboration focuses on the development and commercialization of OliX’s OLX75016, a Phase 1 candidate ...

Eli Lilly's small pop was due to the latest developments in the lab reported by Novo Nordisk (NYSE: NVO), which, like the U.S. company, is doing brisk business with a weight loss drug: Wegovy ...